NCT03485287View on ClinicalTrials.gov

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

June 4, 2019

Study Completion Date

June 4, 2019

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

Midomafetamine HCl

Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later

BEHAVIORAL

Manualized therapy

Non-directive therapy

Trial Locations (2)

V64 1H

British Columbia Centre on Substance Abuse, Vancouver

H2W 1Y9

Dr. Simon Amar, LLC, Montreal

Sponsors

Lead Sponsor

Lykos Therapeutics
All Listed Sponsors
lead

Lykos Therapeutics

INDUSTRY